dc.contributor.author | Cole, M | |
dc.date.accessioned | 2017-03-13T15:04:27Z | |
dc.date.issued | 2013-06-01 | |
dc.identifier.citation | Vol. 34, Iss. 5, pp. 227 - 232 | en_GB |
dc.identifier.uri | http://hdl.handle.net/10871/26524 | |
dc.language.iso | en | en_GB |
dc.publisher | Sweet and Maxwell | en_GB |
dc.rights | © 2013 Sweet & Maxwell and its Contributors | en_GB |
dc.subject | Abuse of dominant position | en_GB |
dc.subject | EU law | en_GB |
dc.subject | Generic medicines | en_GB |
dc.subject | Market definition | en_GB |
dc.subject | Patents | en_GB |
dc.subject | Pharmaceutical industry | en_GB |
dc.subject | Supplementary protection certificates | en_GB |
dc.title | Pharmaceuticals and competition: first strike to the Commission? | en_GB |
dc.type | Article | en_GB |
dc.date.available | 2017-03-13T15:04:27Z | |
dc.identifier.issn | 0144-3054 | |
dc.description | This is the author accepted manuscript. The final version is available from Sweet and Maxwell via the DOI in this record. | en_GB |
dc.identifier.journal | ECLR: European Competition Law Review | en_GB |
refterms.dateFOA | 2023-10-03T18:01:36Z | |